November 1, 2021

Two nationwide population studies on opposite sides of the world confirm links between autoimmune diseases and ADHD, suggest they are from genetic co-aggregation

Both Taiwan and Sweden have universal single-payer health insurance systems that in effect track their entire national populations. With detailed health and other records on millions of individuals, with no significant exclusions, one can essentially eliminate sampling error, and also explore how associations vary by degree of familial/genetic relationship.

A Taiwanese research team used the Taiwan National Health Insurance Research Database to follow 708,517 family triads (father-mother-child) from 2001 through 2011. That's a total of over 2.1 million persons. The database covers over 99% of Taiwan's population.

Noting that previous studies had found links between maternal autoimmune diseases and ADHD in their offspring and that research on associations with paternal autoimmune diseases had been inconclusive, they were particularly interested in exploring the latter.

Children born from 2001 through 2008 were enrolled in the study. The investigators then noted the presence or absence of any autoimmune disease in their parents from 1996 through childbirth.

In Taiwan, expert panels review diagnostic information of severe systemic autoimmune diseases to confirm the diagnosis. Once confirmed, patient co-payments are waived. ADHD diagnoses are by board-certified psychiatrists.

To reduce the effect of confounding variables, adjustments were made for family demographic data (income level and residence), parental ages, parental mental disorders, and sex of children.

The presence of any maternal autoimmune diseases was associated with a 60% greater risk of ADHD in offspring. The risk was especially elevated for inflammatory bowel diseases (2.4 times the risk) and ankylosing spondylitis (twice the risk).

The presence of any paternal autoimmune diseases was also associated with an elevated risk of ADHD in offspring, although only about half as much as for maternal autoimmune diseases, with a 33% greater risk overall. The association was especially pronounced for psoriasis and ankylosing spondylitis, both doubling the risk of ADHD in offspring.

Meanwhile, half a world away, a joint Swedish, Norwegian, and U.S. team used the Swedish national registries to dig further into these associations. They did this by examining data not only from mothers and fathers, but from full siblings, aunts, uncles, and cousins as well, to probe genetic links.

The team used the Swedish registers to identify 5,178,225 individuals born in Sweden between 1960 and 2010 for whom the identity of the biological mother was known, excluding all who died or emigrated before age 10. They then used the registers to identify the aforementioned relatives.

The researchers only included autoimmune diseases with at least two thousand diagnosed individuals in the cohort, to avoid small sample effects.

They adjusted for sex and year of birth, but not "for another covariate that is often adjusted for (e.g. maternal education, family income, parental psychiatric disorder, parental AD [autoimmune disease] as these are likely not true confounders of the association between ADHD and ADD, but may rather represent either mediator between ADHD and AD's, or proxies of ADHD and/or AD risk or alternatively proxies for the associations we aim to measure."

The team found statistically significant associations between ADHD and autoimmune diseases in all categories of relatives. Mothers of children with ADHD were 29% more likely to have an autoimmune disease than those of typically developing children; fathers were 14% more likely to have an autoimmune disease; full siblings 19% more likely; aunts 12% more likely; uncles 7% more likely; and cousins 4% more likely.

Quantitative genetic modeling produced a significant genetic correlation, but no significant environmental correlation. Genetic correlation explained most, if not all, the covariance between ADHD and any autoimmune disease.

The authors concluded, "ADHD was to some degree more strongly associated with maternal than paternal AD's, but by using aunts and uncles in a genetically informative study design, we demonstrate that this difference cannot be readily explained by AD-mediated maternal effects. Quantitative genetic modeling further indicates that the familial co-aggregation of ADHD and ADs is partly due to shared genetic factors. In addition, biological aunts, uncles, and cousins must be assumed to share the little environment with the index individuals, in further support of shared genetic factors underlying the familial co-aggregation. Moreover, both epidemiological and molecular genetics studies have demonstrated positive genetic correlations between ADHD and ADs, in agreement with our findings."

The authors emphasize that these results do not warrant screening for autoimmune diseases among asymptomatic individuals with ADHD.

Tor-Arne Hegvik, Qi Chen, Ralf Kuja-Halkola, Kari Klungsøyr, Agnieszka Butwicka, Paul Lichtenstein, Catarina Almqvist, Stephen V Faraone, Jan Haavik, Henrik Larsson. "Familial co-aggregation of attention-deficit/hyperactivity disorder and autoimmune diseases: a cohort study based on Swedish population-wide registers," International Journal of epidemiology (2021), published online, https://doi.org/10.1093/ije/dyab151.

‍

Hsuan Lee, Ju-Wei Hsu, Shih-Jen Tsai, Kai-Lin Huang, Ya-MeiBai, Tung-Png Su, Tzeng-Ji Chen, Mu-Hong Chen, "Risk of attention deficit hyperactivity and autism spectrum disorders among the children of parents with autoimmune diseases: a nationwide birth cohort study," European Child &Adolescent Psychiatry (2021), published online, https://doi.org/10.1007/s00787-021-01860-0.

Related posts

No items found.

Swedish Nationwide Population Study: Little ADHD Risk from Vacuum-Assisted Delivery

Vacuum-assisted delivery (VAD), also called vacuum extraction, is an assisted vaginal birth method in which a soft plastic cup is attached to the baby’s head with suction to help guide the infant through the birth canal during the pushing stage. Clinicians typically use VAD when labor stalls, the mother is exhausted, or there are concerns about the baby’s heart rate. It is an alternative to a cesarean section (C‑section) that can avoid major surgery. 

In Sweden, VAD is used in about 6%–9% of births, while forceps deliveries are uncommon. When performed with the fetal head at the outlet station (very low in the birth canal), VAD is usually quick and carries minimal risk of injury in full-term babies; these outlet procedures make up roughly half of all VADs. By contrast, several studies have linked VAD performed at mid or low fetal head stations with more serious neonatal complications, such as intracranial bleeding, seizures and, in rare cases, death. 

Despite concerns about short-term neonatal injury after mid/low VAD, research on long-term neurodevelopmental outcomes is limited. A few more recent studies have not found clear links between VAD and adverse long-term outcomes, but most of those studies did not separate outlet from mid/low procedures. 

To address this gap, the authors conducted a nationwide, population-based study in Sweden to compare neonatal and long-term neurodevelopmental outcomes after VAD, and to stratify results by fetal station. They included emergency cesarean delivery and spontaneous vaginal delivery as reference groups to help interpret outcomes after VAD. 

The study used Sweden’s linked national registers, possible because every resident has a personal identification number. Sweden’s tax-funded single-payer health system and nearly universal hospital births mean the registers provide comprehensive, standardized data suitable for long-term follow-up. 

The cohort comprised 630,985 singleton term births from 1997 through 2014. Of these, 73,215 (11.6%) were delivered by VAD, 73,739 (11.7%) by emergency cesarean delivery, and 484,031 (76.7%) by spontaneous vaginal delivery. Among the VAD births, 31,014 (42.4%) were classified as mid/low station and 42,201 (57.6%) as outlet VAD. 

The investigators adjusted their analyses for potential confounders including maternal age; early-pregnancy body-mass index; smoking during pregnancy; the child’s birth year; preeclampsia; gestational diabetes; chorioamnionitis; maternal education level; and maternal medical or psychiatric conditions (type 1 or type 2 diabetes, ADHD, autism spectrum disorder, depression and anxiety). 

After adjustment, VAD overall was associated with a 6% lower risk of later being diagnosed with ADHD compared with the reference groups. When broken down by fetal station, mid/low VAD showed no difference in ADHD risk, while outlet VAD was associated with a 9% lower risk. For comparison, spontaneous vaginal delivery was associated with a 12% lower risk of later ADHD. 

The authors concluded that, in this large nationwide cohort, the findings may offer reassuring evidence about the overall long-term neurodevelopmental safety of VAD.  

‍

‍

‍

Meta-analysis: Almost Three in Four ADHD Patients Receive Pharmaceutical Treatment

The Background:

Management of ADHD relies on both medications and non-medication approaches. Clinical guidelines often recommend medication as the first-line treatment for adults, while non-medication interventions are often preferred for children. Medicines fall into two main groups: stimulants (for example, methylphenidate and amphetamines), which have strong and well-established evidence and are generally considered first choice, and non-stimulants (such as atomoxetine), which are typically used when stimulants are contraindicated, not tolerated, or ineffective. 

How many people with ADHD receive medication is an important indicator of care quality and can be tracked at the national level. Untreated ADHD can affect many areas of life, from physical health, to school and work performance, to relationships emotional well-being. ADHD is associated with poorer quality of life, higher risk of accidents, substance use issues, criminal behavior, educational underachievement, and even increased premature mortality. The condition also places a substantial burden on families and caregivers, so understanding treatment rates matters for individuals and society. 

Most epidemiological research has measured how common diagnosed ADHD is, but the share of those diagnosed who actually receive medication can vary a lot. That variation reflects differences in how ADHD is diagnosed, how easy it is to get treatment, what clinical guidelines recommend, and cultural attitudes toward using medication. 

The Study:

This paper presents the first comprehensive meta-analysis to estimate how common pharmacological treatment is among children, adolescents, and adults with clinically confirmed ADHD. The analysis included only register-based population studies where diagnoses were confirmed by a qualified healthcare professional. Twelve studies meeting these criteria from Europe (the UK, Sweden, Denmark), Asia (Taiwan, South Korea), and North America (Canada, the United States) were used. Notably, these are all high-income areas, and thus unrepresentative of populations in lower-income countries.  

The pooled estimate showed that about 73 percent of diagnosed individuals in prosperous parts of the world with well-developed health care systems were receiving medication, but there was very high variation between studies. 

The Results:

The authors conclude there is substantial global variation in ADHD medication use. Overall, a relatively high proportion of people diagnosed with ADHD are treated with medication, which may reflect improved recognition and access to care. The large differences between studies probably reflect differing health systems, diagnostic rules, treatment definitions, study populations, and reporting practices, and they underline the need for more standardized definitions and reporting to make comparisons more meaningful.  

There is also a need for information from lower-income regions, but that is complicated by an absence of register-based population studies in countries with more limited health care access.

‍

November 4, 2026

Meta-analysis Finds Three- to Eight-fold Higher ADHD Prevalence Among Adults with Substance Use Disorders

The Background:

Because impulsivity is a core feature of ADHD, researchers have suggested it may raise the likelihood that someone will use psychoactive substances (including alcohol) and go on to develop a substance use disorder (SUD). When ADHD and SUD occur together in adolescents, treating one disorder alone usually has little or no positive effect on the other; current guidance therefore recommends treating both conditions at the same time using evidence-based approaches for each. 

Given how much ADHD can worsen outcomes for people with primary SUDs, it is important to identify ADHD in people who are being treated for substance problems. 

The Study:

A recent systematic meta-review found that, by current official criteria, ADHD affects about 7.2% of children and adolescents and about 2.6% of adults (Chaulagain et al., 2023). When adult ADHD is defined without the requirement that symptoms began by age 11, roughly 6.8% of adults meet criteria. A large body of research links ADHD to higher rates of medical problems, poorer quality of life, greater risk of suicide, more accidental injuries, worse educational outcomes, and increased involvement with the criminal justice system. 

The present study is the first meta-analysis to estimate how common clinically diagnosed ADHD is among adults (age 18+) who are in treatment for psychoactive substance use disorders, and to provide those estimates by sex and by the specific substance used. 

The authors included only studies of adults treated for a SUD (including alcohol). Eighty-four studies met the criteria, representing more than 34,000 people. Across all studies, the pooled prevalence of clinically diagnosed ADHD was 22%. 

To put that in context, 22% is about eight times higher than the 2.6% adult prevalence using the stricter official definition, and about three times higher than the 6.8% rate when the childhood-onset requirement is relaxed. By substance, the prevalence was similar for alcohol (24%) and opioids (22%), with no significant difference between males and females. Prevalence among people treated for cocaine use was somewhat lower overall (18%), driven largely by lower rates among women, for whom the rate was no higher than in the general population. Estimates were higher for people using benzodiazepines and cannabis, but those figures are based on a very small number of users (256 and 249 people, respectively) and are therefore less certain. 

The Results: 

The authors conclude: “These findings underscore the need for early identification and treatment of ADHD as most substance use disorders develop in adolescence and young adulthood. While in treatment for ADHD, appropriate screening and management of substance use is possible.” 

‍

October 29, 2026